{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:03:40Z","timestamp":1791594220448,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["SA0051\/2020"],"award-info":[{"award-number":["SA0051\/2020"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006461","name":"Agencia de Innovaci\u00f3n y Desarrollo de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0184-2018"],"award-info":[{"award-number":["PI-0184-2018"]}],"id":[{"id":"10.13039\/501100006461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD20\/00124"],"award-info":[{"award-number":["CD20\/00124"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR18\/00042"],"award-info":[{"award-number":["JR18\/00042"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01471"],"award-info":[{"award-number":["PI19\/01471"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00223"],"award-info":[{"award-number":["PI18\/00223"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI19\/00208"],"award-info":[{"award-number":["FI19\/00208"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00211"],"award-info":[{"award-number":["PI21\/00211"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV18-05-00162"],"award-info":[{"award-number":["NV18-05-00162"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-05-00332"],"award-info":[{"award-number":["NV19-05-00332"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLT006\/17\/ 00199"],"award-info":[{"award-number":["SLT006\/17\/ 00199"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","award":["IN[17]_BBM_CLI_0357 leonardo grant"],"award-info":[{"award-number":["IN[17]_BBM_CLI_0357 leonardo grant"]}],"id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009090","name":"Fundaci\u00f3n de la Sociedad Espa\u00f1ola de Alergolog\u00eda e Inmunolog\u00eda Cl\u00ednica","doi-asserted-by":"publisher","award":["grant 2021"],"award-info":[{"award-number":["grant 2021"]}],"id":[{"id":"10.13039\/501100009090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009090","name":"Fundaci\u00f3n de la Sociedad Espa\u00f1ola de Alergolog\u00eda e Inmunolog\u00eda Cl\u00ednica","doi-asserted-by":"publisher","award":["grant 2017"],"award-info":[{"award-number":["grant 2017"]}],"id":[{"id":"10.13039\/501100009090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009042","name":"Universidad de Sevilla","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009042","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Since the first description of gain of function (GOF) mutations in signal transducer and activator of transcription (STAT) 1, more than 300 patients have been described with a broad clinical phenotype including infections and severe immune dysregulation. Whilst Jak inhibitors (JAKinibs) have demonstrated benefits in several reported cases, their indications, dosing, and monitoring remain to be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, multicenter study recruiting pediatric patients with STAT1 GOF under JAKinib treatment was performed and, when applicable, compared with the available reports from the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten children (median age 8.5\u00a0years (3\u201318), receiving JAKinibs (ruxolitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099) and baricitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091)) with a median follow-up of 18\u00a0months (2\u201342) from 6 inborn errors of immunity (IEI) reference centers were included. Clinical profile and JAKinib indications in our series were similar to the previously published 14 pediatric patients. 9\/10 (our cohort) and 14\/14 patients (previous reports) showed partial or complete responses. The median immune deficiency and dysregulation activity scores were 15.99 (5.2\u201340) pre and 7.55 (3\u201314.1) under therapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0078). Infection, considered a likely adverse event of JAKinib therapy, was observed in 1\/10 patients; JAKinibs were stopped in 3\/10 children, due to hepatotoxicity, pre-HSCT, and absence of response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study supports the potentially beneficial use of JAKinibs in patients with STAT1 GOF, in line with previously published data. However, consensus regarding their indications and timing, dosing, treatment duration, and monitoring, as well as defining biomarkers to monitor clinical and immunological responses, remains to be determined, in form of international prospective multicenter studies using established IEI registries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10875-022-01257-x","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:04:55Z","timestamp":1651197895000},"page":"1071-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations\u201410 Children and Review of the Literature"],"prefix":"10.1007","volume":"42","author":[{"given":"Angela","family":"Dey\u00e0-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaques G.","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9rsio","family":"Roxo-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ramakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Guisado Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Blanco Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya Regina","family":"Abu Jamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Esteve-Sole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Kanderova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Lopez-Corbeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Martinez Pomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mart\u00edn-Nalda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Neth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Olbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"1","key":"1257_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1100102","volume":"365","author":"FL van der Veerdonk","year":"2011","unstructured":"van der Veerdonk FL, Plantinga TS, Hoishchen A, Smeekens SP, Joosten LAB, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1100102.","journal-title":"N Engl J Med"},{"key":"1257_CR2","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","volume":"208","author":"L Liu","year":"2011","unstructured":"Liu L, Okada S, Hong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutation impair IL-17 immunity and underlie chronic mucocutaneous candidaisis. J Exp Med. 2011;208:1635\u201348. https:\/\/doi.org\/10.1084\/jem.20110958.","journal-title":"J Exp Med"},{"issue":"8","key":"1257_CR3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s10875-019-00687-4","volume":"39","author":"T Al Shehri","year":"2019","unstructured":"Al Shehri T, Gilmour K, Gothe F, Loughlin S, Bibi S, Rowan AD, et al. Novel gain-of-function mutation in Stat1 sumoylation site leads to CMC\/CID phenotype responsive to ruxolitinib. J Clin Immunol. 2019;39(8):776\u201385. https:\/\/doi.org\/10.1007\/s10875-019-00687-4.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1257_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/08977194.2012.660936","volume":"30","author":"H Kiu","year":"2012","unstructured":"Kiu H, Nicholson SE. Biology and significance of the JAK\/STAT signaling pathways. Growth Factors. 2012;30(2):88\u2013106. https:\/\/doi.org\/10.3109\/08977194.2012.660936.","journal-title":"Growth Factors"},{"issue":"10","key":"1257_CR5","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3389\/fimmu.2019.01433","volume":"10","author":"O Zimmerman","year":"2019","unstructured":"Zimmerman O, Olbrich P, Freeman AF, Rosen LB, Uzel G, Zerbe CS, et al. STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation. Front Immunol. 2019;10(10):1433. https:\/\/doi.org\/10.3389\/fimmu.2019.01433.","journal-title":"Front Immunol"},{"key":"1257_CR6","doi-asserted-by":"publisher","unstructured":"Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al.. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016; ;127(25):3154\u201364. https:\/\/doi.org\/10.1182\/blood-2015-11-679902.","DOI":"10.1182\/blood-2015-11-679902"},{"issue":"2","key":"1257_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","volume":"141","author":"JW Leiding","year":"2018","unstructured":"Leiding JW, Okada S, Hagin D, Abinun M, Shcherbina A, Balashov DN, et al. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol. 2018;141(2):704-717.e5. https:\/\/doi.org\/10.1016\/j.jaci.2017.03.049.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1257_CR8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","volume":"142","author":"LR Forbes","year":"2018","unstructured":"Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, et al. JAKinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2018.07.020.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1257_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12185-020-02860-7","volume":"112","author":"K Moriya","year":"2020","unstructured":"Moriya K, Suzuki T, Uchida N, Nakano T, Katayama S, Irie M, Rikiishi T, Niizuma H, Okada S, Imai K, Sasahara Y, Kure S. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation. Int J Hematol. 2020;112(2):258\u201362. https:\/\/doi.org\/10.1007\/s12185-020-02860-7.","journal-title":"Int J Hematol"},{"key":"1257_CR10","doi-asserted-by":"publisher","unstructured":"Chaimowitz NS, Ebenezer SJ, Hanson IC, Anderson M, Forbes LR. STAT1 gain of function, type 1 diabetes, and reversal with JAK inhibition. N Engl J Med. 2020t 8;383(15):1494\u20131496.https:\/\/doi.org\/10.1056\/NEJMc2022226.","DOI":"10.1056\/NEJMc2022226"},{"key":"1257_CR11","doi-asserted-by":"publisher","unstructured":"Bloomfield M, Kanderov\u00e1 V, Para\u010dkov\u00e1 Z, Vrabcov\u00e1 P, Svato\u0148 M, Fro\u0148kov\u00e1 E, et al. A. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018;38(5):589\u2013601. https:\/\/doi.org\/10.1007\/s10875-018-0519-6","DOI":"10.1007\/s10875-018-0519-6"},{"key":"1257_CR12","doi-asserted-by":"publisher","unstructured":"Vargas-Hern\u00e1ndez A, Mace EM, Zimmerman O, Zerbe CS, Freeman AF, Rosenzweig S, Leiding JW, Torgerson T, Altman MC, Schussler E, Cunningham-Rundles C, Chinn IK, Carisey AF, Hanson IC, Rider NL, Holland SM, Orange JS, Forbes LR. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2018 Jun;141(6):2142\u20132155.e5. https:\/\/doi.org\/10.1016\/j.jaci.2017.08.040.","DOI":"10.1016\/j.jaci.2017.08.040"},{"issue":"22","key":"1257_CR13","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1056\/NEJMc2031081","volume":"383","author":"B Neven","year":"2020","unstructured":"Neven B, Al Adba B, Hully M, Desguerre I, Pressiat C, Boddaert N, et al. JAK inhibition in the Aicardi-Gouti\u00e8res syndrome. N Engl J Med Mass Med Soc. 2020;383(22):2190\u20133. https:\/\/doi.org\/10.1056\/NEJMc2031081.","journal-title":"New England Journal of Medicine, Massachusetts Medical Society"},{"issue":"12","key":"1257_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.717388","volume":"17","author":"J Hadjadj","year":"2021","unstructured":"Hadjadj J, Fr\u00e9mond ML, Neven B. Emerging place of JAK inhibitors in the treatment of inborn errors of immunity. Front Immunol. 2021;17(12): 717388. https:\/\/doi.org\/10.3389\/fimmu.2021.717388.","journal-title":"Front Immunol"},{"issue":"5","key":"1257_CR15","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","volume":"145","author":"VK Tesch","year":"2020","unstructured":"Tesch VK, Abolhassani H, Shadur B, Zobel J, Mareika Y, Sharapova S, et al. Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. J Allergy Clin Immunol. 2020;145(5):1452\u201363. https:\/\/doi.org\/10.1016\/j.jaci.2019.12.896.","journal-title":"J Allergy Clin Immunol"},{"key":"1257_CR16","doi-asserted-by":"publisher","unstructured":"Seidel MG, Tesch VK, Yang L, Hauck F, Horn AL, Smolle MA, et al The immune deficiency and dysregulation activity (IDDA2.1 \u2018kaleidoscope\u2019) score and other clinical measures in inborn errors of immunity. J Clin Immunol. 2021 Nov 19. https:\/\/doi.org\/10.1007\/s10875-021-01177-2. Epub ahead of print","DOI":"10.1007\/s10875-021-01177-2"},{"issue":"4","key":"1257_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10875-020-00943-y","volume":"41","author":"B Kayaoglu","year":"2021","unstructured":"Kayaoglu B, Kasap N, Yilmaz NS, Charbonnier LM, Geckin B, Akcay A, et al. Stepwise reversal of immune dysregulation due to STAT1 gain-of-function mutation following ruxolitinib bridge therapy and transplantation. J Clin Immunol. 2021;41(4):769\u201379. https:\/\/doi.org\/10.1007\/s10875-020-00943-y.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1257_CR18","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1097\/MPG.0000000000002854","volume":"71","author":"KP Acker","year":"2020","unstructured":"Acker KP, Borlack R, Iuga A, Remotti HE, Soderquist CR, Okada S, et al. Ruxolitinib response in an infant with very-early-onset inflammatory bowel disease and gain-of-function STAT1 mutation. J Pediatr Gastroenterol Nutr. 2020;71(4):e132\u20133. https:\/\/doi.org\/10.1097\/MPG.0000000000002854.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1257_CR19","unstructured":"Full prescribing information JAKAVI EMA. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jakavi-epar-product-information_es.pdf. Accessed 04\/08\/2021."},{"key":"1257_CR20","unstructured":"Full prescribing information FDA: JAKAVI https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202192s017lbl.pdf. Accessed 04\/08\/2021."},{"issue":"10","key":"1257_CR21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/pbc.25575","volume":"62","author":"ML Loh","year":"2015","unstructured":"Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children\u2019s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015;62(10):1717\u201324. https:\/\/doi.org\/10.1002\/pbc.25575.","journal-title":"Pediatr Blood Cancer"},{"key":"1257_CR22","doi-asserted-by":"publisher","unstructured":"Wegehaupt O., Muckenhaupt T., Johnson M.B. et al. Ruxolitinib controls lymphoproliferation and diabetes in a STAT3-GOF patient. J Clin Immunol 40, 1207\u20131210 (2020).https:\/\/doi.org\/10.1007\/s10875-020-00864-w","DOI":"10.1007\/s10875-020-00864-w"},{"issue":"7","key":"1257_CR23","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352. https:\/\/doi.org\/10.1172\/JCI98814.","journal-title":"J Clin Invest"},{"issue":"10","key":"1257_CR24","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank DB, et al. Janus kinase inhibition in the Aicardi-Gouti\u00e8res syndrome. N Engl J Med. 2020;383(10):986\u20139. https:\/\/doi.org\/10.1056\/NEJMc2001362.","journal-title":"N Engl J Med"},{"issue":"1","key":"1257_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaci.2018.02.045","volume":"142","author":"K Meesilpavikkai","year":"2018","unstructured":"Meesilpavikkai K, Dik WA, Schrijver B, Nagtzaam NMA, Posthumus-van Sluijs SJ, van Hagen PM, et al. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). J Allergy Clin Immunol. 2018;142(1):328-330.e2. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.045.","journal-title":"J Allergy Clin Immunol"},{"key":"1257_CR26","unstructured":"Registry Working Party. Immune deficiency and dysregulation activity (IDDA) score. https:\/\/esid.org\/Working-Parties\/Registry-Working-Party\/Studies\/IDDA-Score. Accessed: 20 December 2021"},{"issue":"2","key":"1257_CR27","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25(2):e328\u201334. https:\/\/doi.org\/10.1634\/theoncologist.2019-0627.","journal-title":"Oncologist"},{"issue":"7","key":"1257_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/17474086.2017.1337507","volume":"10","author":"I Saeed","year":"2017","unstructured":"Saeed I, McLornan D, Harrison CN. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Rev Hematol. 2017;10(7):617\u201325. https:\/\/doi.org\/10.1080\/17474086.2017.1337507.","journal-title":"Expert Rev Hematol"},{"key":"1257_CR29","doi-asserted-by":"publisher","unstructured":"Sant\u2019Antonio E, Bonifacio M, Breccia M, Rumi E. A journey through infectious risk associated with ruxolitinib. Br J Haematol. 2019;187(3):286\u2013295. https:\/\/doi.org\/10.1111\/bjh.16174.","DOI":"10.1111\/bjh.16174"},{"key":"1257_CR30","doi-asserted-by":"publisher","unstructured":"Ballesta B, Gonz\u00e1lez H, Mart\u00edn V, Ballesta JJ. Fatal ruxolitinib-related JC virus meningitis. J Neurovirol. 2017;23(5):783\u201378. https:\/\/doi.org\/10.1007\/s13365-017-0558-4.","DOI":"10.1007\/s13365-017-0558-4"},{"key":"1257_CR31","doi-asserted-by":"publisher","unstructured":"Nakayama K, Nakamura M, Konishi A, Kaneko S, Nakamichi K, Saijo M, Yakushiji Y, Kusaka H. JC virus granule cell neuronopathy associated with ruxolitinib: a case report and review of the literature. eNeurologicalSci. 2020;21:100269 . https:\/\/doi.org\/10.1016\/j.ensci.2020.100269","DOI":"10.1016\/j.ensci.2020.100269"},{"key":"1257_CR32","doi-asserted-by":"publisher","unstructured":"Reoma LB, Trindade CJ, Monaco MC, Solis J, Montojo MG, Vu P, et al A. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann Neurol. 2019;86(6):878\u2013884. https:\/\/doi.org\/10.1002\/ana.25608","DOI":"10.1002\/ana.25608"},{"key":"1257_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJMc1302135","volume":"369","author":"R Wathes","year":"2013","unstructured":"Wathes R, Moule S, Milojkovic D. Progressive multifocal leucoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369:197\u20138. https:\/\/doi.org\/10.1056\/NEJMc1302135.","journal-title":"N Engl J Med"},{"key":"1257_CR34","doi-asserted-by":"publisher","unstructured":"Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. 2014;2014. pii: bcr2014204950. https:\/\/doi.org\/10.1136\/bcr-2014-204950","DOI":"10.1136\/bcr-2014-204950"},{"issue":"1","key":"1257_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00277-018-3405-7","volume":"98","author":"H Gill","year":"2019","unstructured":"Gill H, Leung GMK, Seto WK, Kwong YL. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment. Ann Hematol. 2019;98(1):215\u20138. https:\/\/doi.org\/10.1007\/s00277-018-3405-7.","journal-title":"Ann Hematol"},{"issue":"1","key":"1257_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/leu.2013.235","volume":"28","author":"G Caocci","year":"2014","unstructured":"Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28(1):225\u20137. https:\/\/doi.org\/10.1038\/leu.2013.235.","journal-title":"Leukemia"},{"key":"1257_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJMc1302895","volume":"369","author":"RA Goldberg","year":"2013","unstructured":"Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369:681\u20133. https:\/\/doi.org\/10.1056\/NEJMc1302895.","journal-title":"N Engl J Med"},{"issue":"5","key":"1257_CR38","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","volume":"139","author":"KG Weinacht","year":"2017","unstructured":"Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629-1640.e2. https:\/\/doi.org\/10.1016\/j.jaci.2016.11.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1257_CR39","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.jaip.2020.05.008","volume":"8","author":"E Cordero","year":"2020","unstructured":"Cordero E, Goycochea-Valdivia W, Mendez-Echevarria A, Allende LM, Alsina L, Bravo Garc\u00eda-Morato M, et al. Executive summary of the Consensus Document on the diagnosis and management of patients with primary immunodeficiencies. J Allergy Clin Immunol Pract. 2020;8(10):3342\u20137. https:\/\/doi.org\/10.1016\/j.jaip.2020.05.008.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1257_CR40","unstructured":"Registry Working Party. Resources. https:\/\/esid.org\/Working-Parties\/Inborn-Errors-Working-Party-IEWP\/Studies\/Multicentric-retrospective-study-on-JAKinib-treatment-of-patients-with-IEI-of-the-JAK-STAT-pathway. Accessed 21 December 2021"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01257-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-022-01257-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01257-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T20:06:48Z","timestamp":1661371608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-022-01257-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s10875-022-01257-x","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was reviewed and approved by the local ethics committees of the participating centers. Informed consent was obtained from study participants and\/or their legal guardians according to the requirements of the local ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of their individual details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}